Predictors and Recurrence Patterns After Radical Surgery in Ampulla of Vater Cancer: Comparative Analysis Between Early and Late Recurrence

Zheng-Yun Zhang¹, Da-Wei Liu², Di-Si Hao² and Zun-Qiang Zhou¹*

¹Department of Surgery, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China, ²Department of Surgery, Heilongjiang Provincial Hospital Affiliated to Harbin Institute of Technology, Harbin, China

Objective: Tumor recurrence remains the main dilemma after surgical treatment of ampulla of Vater carcinoma. This study was designed to identify the prognostic factors and evaluate the recurrence patterns of ampulla of Vater cancer.

Methods: A total of 286 patients who underwent surgical resection of ampulla of Vater cancer in two medical centers from January 2000 to October 2016 were collected. Data on clinicopathologic factors, survival rate, and recurrence patterns were retrospectively analyzed.

Results: A total of 158 patients (55.2%) survived without evidence of recurrence (non-recurrence), whereas 65 (22.7%) and 63 patients (22.1%) suffered from recurrence of the disease within 12 months (early recurrence) and after 12 months (late recurrence), respectively. Early-recurrence patients exhibited a more advanced disease (advanced tumor stage, lymph node involvement, pancreas invasion, and late TNM stage) than late-recurrence patients. The first or primary location of cancer recurrence in 33 patients (25.8%) was locoregional. Metastasis developed in the liver in 30 patients (23.4%), peritoneum in 13 patients (10.2%), lungs in 10 patients (7.8%), and para-aortic or superior mesenteric artery lymph node in 10 patients (7.8%). Multiple metastases were observed in 26 patients (20.3%).

Conclusion: The most common patterns of postoperative recurrence are locoregional and recurrent liver metastasis. The recurrence patterns with the worst prognosis are peritoneal and multiple metastases.

Keywords: adenocarcinoma, ampulla of Vater, predictors of recurrence, recurrence pattern, radical surgery

INTRODUCTION

Carcinoma of the ampulla of Vater has a relatively higher resection rate and more favorable prognosis than other malignant tumors of the periampullary region. The 5-year survival rate of ampulla of Vater cancer after radical surgery ranges from 35.0% to 62.7% (1–4). However, tumor recurrence frequently remains the main problem after surgical treatment of ampulla of
Vater carcinoma, and recurrences are often found in various forms and at more than one site simultaneously. Therefore, confirming the patterns and evaluating the risk factors of recurrence are difficult. Numerous studies have investigated the clinicopathologic aspects of ampulla of Vater carcinoma, but most have focused only on the prognosis or survival of the disease (5, 6). An examination of the predictors and recurrence patterns can establish the criteria for postoperative adjuvant therapy, which can postpone recurrence and improve survival (5, 7, 8). In the present study, patterns of relapses were investigated, and the correlation between histopathologic factors and recurrence was evaluated to provide a basis for the development of further therapy.

METHODS

Patients
The findings on 328 consecutive patients who were operated for ampulla of Vater adenocarcinoma from January 2000 to October 2016 in Shanghai Jiao Tong University Affiliated Sixth People’s Hospital and Heilongjiang Provincial Hospital Affiliated to Harbin Institute of Technology were retrospectively reviewed. Forty-two patients who underwent palliative operation were excluded. A total of 286 patients underwent pancreaticoduodenectomy with regional lymphadenectomy. We routinely performed lymph node dissection in the hilar region, the upper and lower edges of the pancreas, and around the celiac trunk vessels, without cleaning the lymph nodes near the inferior vena cava. The median number of lymph node dissection was 23 (16–44). Rapid frozen pathological examination was performed routinely during the operation, and the benign and malignant tumors of the cutting edge were determined. The medical records of all 286 patients were retrospectively reviewed for demographics, laboratory findings on admission and postoperation, types of procedure, operative findings, and histopathologic findings. Percutaneous transhepatic biliary drainage or endoscopic nasobiliary drainage was routinely used to relieve obstructive jaundice before operation if the bilirubin level was higher than 10 mg/dL. The type of resection, either Whipple or pylorus-preserving pancreaticoduodenectomy, was based on the surgeon’s judgment. Perioperative and follow-up details were compared among patients with tumor recurrence and non-recurrence and early and late recurrence. The time from operation to recurrence varied (1–78 months). The median time of recurrence was 11 months. For the purpose of data analysis, patients with recurrence were therefore operationally categorized into early- or late-recurrence groups with a cutoff time point of 12 months. This study was conducted according to the principles outlined in the Declaration of Helsinki, and patients provided written informed consent.

Histopathology
All tumors were adenocarcinomas that originated in the ampulla of Vater. Histologic differentiation was recorded as well, moderately, or poorly differentiated. Tumor size was measured from surgical specimens before formalin fixation. The tumor and TNM stages were defined according to the American Joint Committee on Cancer (AJCC, 8th Edition) classification of 2016 (9). The resection margin was evaluated by a pathologist. R0 resection indicated that the resection margins of the pancreas, common bile duct, duodenum, and retropancreatic tissue were histologically free of carcinoma. R1 resection indicated histologically positive for carcinoma cells in the resection margin, but grossly free, based on the surgeon’s judgement (10–12).

Definition of complications and follow-up
Follow-up at 3-month intervals comprised physical examination, laboratory tests, and tumor markers (CA199). Abdominal computed tomography was arranged every 3 months in the first year and then every 6 months in the second year. Radiography of the thorax, bone scan, and computed tomography of the brain were performed if clinical examination led to a suspicion of metastasis. Disease relapse was defined as a biopsy-proven disease or radiologic evidence of recurrence. Recurrence was categorized as locoregional or metastatic. Local recurrence was defined as a recurrent retroperitoneal mass or regional node, and metastasis was defined as a relapse of the disease at a distant site, either a visceral organ or a non-regional lymph node. Multiple metastases were defined as more than one site of metastases. The primary endpoint of the study was death, and the primary criterion of follow-up was survival time.

Statistical analysis
Continuous variables were expressed as median and range or mean ± standard deviation, while categorical variables were reported as number and percentage. Chi-square test was used for nominal data, and univariate analysis was performed with $\chi^2$ test or Fisher’s exact test for categorical variables. Comparison between the early- and late-recurrence groups was separately performed. For those that did not follow normal distributions, non-parametric Mann–Whitney U test was used. Disease-free survival was estimated with the Kaplan–Meier method and compared with log-rank test. Disease-free survival was measured from the date of surgery to the date of recurrence or last contact. Factors found to be statistically significant (p < 0.1) by univariate analysis were subjected to multivariate analysis with Cox proportional-hazard regression using forward stepwise procedure (13). Data were considered significant at $p < 0.05$. SPSS 20.0 statistical software (SPSS, Chicago, IL) was used for all statistical analyses.

RESULTS

Demographics
A total of 286 patients were enrolled in the study. The non-recurrence group consisted of 158 patients (55.2%), the early-recurrence group consisted of 65 patients (22.7%), and the
late-recurrence group consisted of 63 patients (22.1%). No statistical difference was observed between the non-recurrence and recurrence groups in terms of age, gender, body mass index (BMI), total bilirubin, or operative methods. The median follow-up periods in the non-recurrence and recurrence groups were 59 months (range: 1 to 178 months) and 31.5 months (range: 2 to 111 months), respectively. The median times from surgery to recurrence in the early- and late-recurrence groups were 6 months (range: 1 to 11 months) and 30 months (range: 12 to 78 months), respectively. The non-recurrence group had a lower preoperative or postoperative CA199 level than the recurrence group ($p < 0.01$) (Table 1). To focus on distinctions between early and late recurrence, the patients’ demographics are also shown in Table 1. The early-recurrence group had a higher preoperative CA199 level than the late-recurrence group ($p < 0.05$). Early-recurrence patients did not have a significantly higher post or recurrent CA199 level than late-recurrence patients. No statistical significance was observed between the early- and late-recurrence groups in terms of age, gender, BMI, total bilirubin, or operative methods. A total of 89 patients (31.1%) received postoperative adjuvant chemotherapy. No patients received neoadjuvant or intraoperative radiation therapy. Concurrent chemotherapy for most patients included continuous infusion of 5-fluorouracil and gemcitabine.

### Histopathologic findings
The results of univariate analysis of risk factors and histopathologic results between the non-recurrence and recurrence groups and the early- and late-recurrence groups are shown in Table 2. No correlation in tumor size was observed among the four groups. With regard to tumor stage, 3.1% of patients in the early-recurrence group had a T1 lesion, while 96.9% had T2, T3, or T4 lesions; meanwhile, 85.7% and 71.5% of patients in the late- and non-recurrence groups had T2, T3, or T4 lesions, respectively. A total of 56 patients (43.8%) and 37 patients (23.4%) had pancreatic invasion (T3) in the recurrence and non-recurrence groups, respectively. In the recurrence group, 34 patients (52.3%) and 22 patients (34.9%) had pancreatic invasion in the early-recurrence and late-recurrence groups, respectively. All patients in the non-recurrence groups had complete resection (R0 resection); however, three and two patients in the early-recurrence and late-recurrence groups had residual microscopic disease (R1 resection), respectively ($p > 0.05$). No significant difference in the number of total dissected lymph nodes was observed among the four groups. The ratio of lymph node involvement was 19.6% and 39.8% in the non-recurrence and recurrence groups ($p < 0.001$) and 50.8% and 30.2% in the early- and late-recurrence groups, respectively ($p < 0.05$). The ratio of lymphovascular invasion in the non-recurrence group was 24.1%, which was significantly lower than that in the recurrence group (39.1%) ($p < 0.001$). In the early-recurrence group, the ratio of lymphovascular invasion was 50.8%, which was higher than that in the late-recurrence group (27%) ($p < 0.01$). The ratio of perineural invasion in the non-recurrence group was lower than that in the recurrence group ($p < 0.001$), but no statistical significance was observed between the early- and late-recurrence groups. Furthermore, the ratios of moderate and poor differentiation were higher in the early-recurrence group (72.3% and 20% compared with 60.3% and 4.8% in the late-recurrence group, $p < 0.01$). The non-recurrence patients had the disease at an early stage (51.3% in stage I, 31.0% in stage II, and 17.7% in stage III), whereas the recurrence patients had the disease at an advanced stage (28.1% in stage I, 50% in stage II, and 21.9% in stage III, $p < 0.001$). The early-recurrence patients had a more advanced disease (16.9% in stage I, 58.5% in stage II, and 24.6% in stage III) than late-recurrence ones (39.7% in stage I, 41.3% in stage II, and 19% in stage III, $p < 0.05$).

### Recurrence patterns
A total of 158 patients (55.2%) in the non-recurrence group had no recurrent disease during follow-up. Cancer recurrence was

### TABLE 1 | Demographics of patients with ampullary cancer who underwent radical resection.

| Demographics          | Non-recurrence | Recurrence | P value | Early recurrence | Late recurrence | P value |
|-----------------------|----------------|------------|---------|------------------|----------------|---------|
| Patients, n (%)       | 158 (55.2%)    | 128 (44.8%)| NS      | 65 (22.7%)       | 63 (22.1%)     | NS      |
| Age, mean ± SD        | 65.1 ± 11.1    | 66.2 ± 11.4| NS      | 64.7 ± 11.4      | 67.8 ± 11.1    | NS      |
| Gender, (F/M)         | 74/84          | 53/75      | NS      | 21/44            | 32/31          | NS      |
| BMI, mean ± SD        | 23.5 ± 2.8     | 23.1 ± 3.4 | NS      | 22.7 ± 3.6       | 23.5 ± 3.2     | NS      |
| Total bilirubin (mg/dL)| 6.1 (0.5-43.1) | 4.8 (0.6-26.6)| NS | 7.4 ± 6.2       | 5.6 ± 5.5     | NS      |
| Operative procedure, n (%) | NS        | NS        | NS      | 16               | 12             |         |
| Whipple               | 25             | 28         |         | 16               | 12             |         |
| PPPD                  | 133            | 100        |         | 49               | 51             |         |
| Adjuvant chemotherapy | 20             | 69         | <0.001  | 35               | 34             | NS      |
| CA199 (pre-operation) (U/dL)| 134.0 (6.0-4480.0) | 264.5 (1.5-10900.0) | <0.01 | 57.6 (1.5-1800.0) | 32.6 (2.6-10900.0) | <0.05 |
| CA199 (1 month post-operation) (U/dL)| 8.9 (0.6-53.7) | 246.0 (0.3-20600.0) | <0.01 | 14.3 (0.3-20600.0) | 10.7 (1.6-1883.0) | NS      |
| CA199 (Recurrence) (U/dL)| 71.3 (1.0-41900.0) | 78.1 (51.0-41900.0) | 74.5 (43.0-42500.0) | NS |
| Follow-up (months, median[range]) | 59.0 (1.0-178.0) | 31.5 (2.0-111.0) | 16.0 (2.0-47.0) | 46.0 (15.0-111.0) |

NS: not significant.
observed in 128 (44.8%) patients, and the first or primary location of cancer recurrence was locoregional in 33 patients (25.8%). Metastasis developed in the liver in 30 patients (23.4%), peritoneum in 13 patients (10.2%), lungs in 10 patients (7.8%), and para-aortic or superior mesenteric artery (SMA) lymph node in 10 patients (7.8%). Multiple metastases were observed in 26 patients (20.3%). The recurrence of other diseases (e.g., bone metastasis and Virchow’s lymph node) was observed in six patients (4.7%). To focus on distinctions between early and late recurrence, the details of recurrence patterns are shown in Table 3. The recurrence patterns were similar between the early- and late-recurrence groups.

**Patients’ survival**

The mean survival time for the entire patient population was 91.7 months (95% CI: 81.8–101.7). The estimated overall survival rates at 3 and 5 years were 69.4% and 55.5%, respectively. The median survival times (from operation to death) in the early- and late-recurrence groups were 16 (2–68) and 46 (15–11) months (p < 0.001) (Figure 1). The patterns of the recurrence group showed that peritoneal seeding, para-aortic/SMA lymph node metastasis, and multiple metastases significantly influenced survival as indicated in the univariate analysis (p < 0.05) (Figure 2). The median time from disease recurrence to death was 9 (0–57) and 16 (0–76) months in the early- and late-recurrence groups (p < 0.05), respectively. The mean survival times of patients with peritoneal seeding and multiple metastases were shorter than those of others at 20.8 and 26.4 months, respectively. Eighty-nine patients (31.1%) received postoperative adjuvant chemotherapy. Seventeen patients with chemotherapy for local recurrence showed an improved survival rate compared with 16 patients without chemotherapy.

### TABLE 2 | Histopathologic findings in patients: results of univariate analysis.

|                          | Non-recurrence | Recurrence | P value | Early- recurrence | Late- recurrence | P value |
|--------------------------|----------------|------------|---------|-------------------|-----------------|---------|
| Patients, n (%)          | 158 (55.2%)    | 128 (44.8%)|         | 65 (22.7%)        | 63 (22.1%)      |         |
| Tumor size (cm)          | 2.2 ± 1.2      | 2.4 ± 1.3 | NS      | 2.6 ± 1.3         | 2.1 ± 1.2       | NS      |
| Tumor stage, n (%)       |                |            |         |                   |                 |         |
| T1 (duodenal invasion)   | 45 (28.5%)     | 11 (8.6%)  | <0.001  | 2 (3.1%)          | 9 (14.3%)       | <0.001  |
| T2 (pancreas invasion)   | 48 (30.4%)     | 35 (27.3%) | NS      | 15 (23.1%)        | 20 (31.7%)      | NS      |
| T3 (peritoneum)          | 37 (23.4%)     | 56 (43.8%) | <0.001  | 34 (52.3%)        | 22 (34.9%)      | <0.05   |
| T4 (spleen, stomach, liver) | 28 (17.7%)  | 26 (20.3%) |          | 14 (21.5%)        | 12 (19.0%)      |         |
| Resection margin, n (%)  |                |            |         |                   |                 |         |
| R0                       | 158            | 123        |         | 62                | 61              |         |
| R1                       | 0              | 5          | 3       | 2                 |                 |         |
| R2                       | 0              | 0          | 0       | 0                 |                 |         |
| Resected lymph node (median[range]) | 9 (0-50) | 9 (0-55) | NS | 10 (0-55) | 9 (0-24) | NS |
| Positive lymph node (median[range]) | 4 (0-9) | 6 (0-14) | <0.001 | 6 (0-14) | 7 (0-11) | <0.01 |
| Lymph node status, n (%) |                |            |         |                   |                 |         |
| Negative                 | 127 (80.4%)    | 77 (60.2%) |         | 32 (49.2%)        | 44 (69.8%)      |         |
| Positive                 | 31 (19.6%)     | 51 (39.8%) |         | 33 (50.8%)        | 19 (30.2%)      |         |
| Lymphovascular invasion  |                |            |         |                   |                 |         |
| Negative                 | 120 (75.9%)    | 78 (60.9%) | <0.001  | 32 (49.2%)        | 46 (73.0%)      | <0.01   |
| Positive                 | 38 (24.1%)     | 50 (39.1%) |         | 33 (50.8%)        | 17 (27.0%)      |         |
| Perineural invasion      |                |            |         |                   |                 |         |
| Negative                 | 138 (87.3%)    | 92 (71.9%) | <0.001  | 42 (64.6%)        | 50 (79.4%)      | <0.001  |
| Positive                 | 20 (12.7%)     | 36 (28.1%) |         | 23 (35.4%)        | 13 (20.6%)      |         |
| Differentiation, n (%)   |                |            |         |                   |                 | <0.001  |
| Well                     | 79 (50.0%)     | 27 (21.1%) |         | 5 (7.7%)          | 22 (34.9%)      |         |
| Moderate                 | 71 (44.9%)     | 85 (66.4%) |         | 47 (72.3%)        | 38 (60.3%)      |         |
| Poor                     | 8 (5.1%)       | 16 (12.5%) |         | 13 (20.0%)        | 3 (4.8%)        |         |
| AJCC TNM Stage, n (%)    |                |            |         |                   |                 | <0.05   |
| Stage I                  | 81 (51.3%)     | 36 (28.1%) | <0.001  | 11 (16.9%)        | 25 (39.7%)      |         |
| Stage II                 | 49 (31.1%)     | 64 (40.0%) |         | 38 (58.5%)        | 26 (41.3%)      |         |
| Stage III                | 28 (17.7%)     | 28 (21.9%) |         | 16 (24.6%)        | 12 (19.0%)      |         |

NS: not significant.
In the univariate analysis, tumor stage, resection margin, lymph node involvement, lymphovascular invasion, perineural invasion, tumor differentiation, AJCC TNM stage, and chemotherapy were the significant predictors of recurrence (Table 4). In multivariate analysis, histologic differentiation (RR = 2.4, 95% CI: 1.9–3.9, p < 0.01), lymphovascular invasion (RR = 2.2, 95% CI: 1.5–3.0, p < 0.01), peritoneal seeding (RR = 12.2, 95% CI: 5.6–43.8, p < 0.01), and multiple metastases (RR = 6.7, 95% CI: 2.4–18.3, p < 0.01) were the significant predictors of early recurrence. Lymphovascular invasion (RR = 2.5, 95% CI: 1.2–3.7, p < 0.01), peritoneal seeding (RR = 6.9, 95% CI: 3.5–9.6, p < 0.01), and multiple metastases (RR = 5.4, 95% CI: 2.1–7.8, p < 0.01) were the significant predictors of late recurrence (Table 5). Further analysis showed that the majority of the patients in early recurrence group had moderate (72.3%) and poor (20.0%) differentiation lesions (Table 2).

**DISCUSSION**

Carcinoma of the ampulla of Vater is a rare neoplasm, but has a relatively favorable prognosis compared with other perampullary neoplasms, such as those of the pancreatic head or distal bile duct (12, 14, 15). The difficulties associated with surgery include higher frequencies of regional or distant lymph node metastases and vascular involvement, and positive resection margins in pancreatic and retroperitoneal tissues. Radical resections increase margin negativity and life expectancy; however, the extend of the surgery applied is controversial. Thus, western and eastern centers may use different approaches (16). Nevertheless, similar to other malignancies of this region, tumor recurrence after radical resection of ampulla of Vater carcinoma eventually leads to the death of the patient (17). In the literature, several risk factors for ampullary cancer have been identified, including tumor size, histologic grade, invasion depth, tumor morphology, lymph node involvement, blood

---

**TABLE 3 | Recurrence patterns in 128 patients with ampullary of vater cancer who underwent radical surgery, comparing early and late recurrence group.**

| Local recurrence | Late recurrence | P value |
|------------------|----------------|---------|
| Early recurrence | 13 (20%)       | 20 (31.8%) | NS |
| Metastasis       | 34 (52.3%)     | 29 (46.0%) | NS |
| Liver metastasis | 18             | 12       | NS |
| Peritoneal carcinomatosis | 9 | 4 | NS |
| Lung metastasis  | 3              | 7        | NS |
| Paraortic/SMA LN | 4             | 6        | NS |
| Multiple metastasis | 16 (24.6%) | 10 (15.9%) | NS |
| Others*          | 2 (3.1%)       | 4 (6.3%)  | NS |

*Others including bone, colon and Virchow’s lymph node metastases, NS: not significant.

---

**FIGURE 1 | Median survival time (from operation to death) in the early and late-recurrence groups at 16 (2-68) months vs 46 (15-111) months (p < 0.001).**
transfusion, and positive resection margin (18, 19). In this study, lymph node involvement, lymphovascular invasion, histologic differentiation, perineural invasion, and AJCC TNM stage were identified as the significant predictors of recurrence.

Lymph node involvement is a significant predictor of poor prognosis (5). In this study, regional lymphadenectomy, not including para-aortic and distant nodes as in radical lymphadenectomy, was performed. The ratio of lymph node involvement was 39.8% in the recurrence group, 50.8% in the early-recurrence group, and 30.2% in the late-recurrence group (p < 0.05). Further comparisons between early- and late-recurrence groups showed that the effects of lymph node involvement and tumor differentiation were significant. Lymph node involvement can indicate more advanced disease characteristics.

The 5-year survival rate in patients with lymph node involvement ranged from 0% to 41% and that in patients without it ranged from 67% to 81% (20). Our series showed similar results: 82 patients with lymph node involvement had a significantly shorter mean survival time (68.1 months) and 5-year survival (38.0%) than patients without lymph node involvement (5-year survival: 62.4%).

Klempnauer et al. identified the determinants of long-term survival after resection of ampullary cancer by comparing short- and long-term survivors (21). They found that tumor size, lymph node metastasis, Union for International Cancer Control stage, and grading significantly affect long-term survival, but only tumor size showed independent prognostic significance in multivariate analysis. Delcore et al. reported that tumor size was one of the independent factors for recurrence and 5-year survival (22). By contrast, Begar et al. showed that pancreatic invasion, not tumor size, was the pivotal factor for survival and recurrence (23). The present study obtained similar results: The number of patients with pancreatic invasion in the recurrence group (n = 56, 43.8%) was higher than that in the non-recurrence group (n = 37, 23.4%) (p < 0.001). Once the tumors penetrate the sphincter of Oddi, ampullary cancer causes nodal involvement and recurrences. The depth of invasion is a significant parameter of the degree of tumor spread and prognosis (7, 5). From the anatomical character of the ampulla of Vater, the pancreatic side of the duodenum has the lymphovascular supplement of the peripancreatic region. If the large tumor grows into the duodenal lumen but not into the pancreas, subsequent metastasis will not develop. Therefore, the negative effect should come from pancreatic invasion, not the large tumor size. The disease-free and overall survival in patients with intestinal subtype was superior to that in patients with pancreaticobiliary subtype.

Several reports showed through univariate analysis that tumor differentiation was also a predictor of survival, but the same was not the case when multivariate analysis was used. The 5-year survival rate was reported at 82% in patients with a well-differentiated tumor and 37% in patients with a moderately to poorly differentiated tumor. In this series, the
5-year survival rates were dismal in those with a well-differentiated and moderately or poorly differentiated tumor. However, the differentiation had no influence on liver metastasis or local recurrence.

The TNM staging system is a popular predictor of survival, but survival rates vary in different reports. In some reports, the 5-year survival rate was 76%–100% for patients with stage I disease, 21%–70% for stage II disease, 10%–27% for stage III disease, and 0% for stage IV disease. In this series, the 5-year survival rate was 72.1% for patients with stage I disease, 39.9% for stage II disease, and 31.7% for stage III disease (25, 26).

Very few previous studies have focused on the recurrence patterns of ampulla of Vater carcinoma after surgical resection, even if these significantly affect patients’ survival. The most common pattern of relapse in ampullary cancer is liver metastasis, which ranges from 53%–67%, followed by distant lymph nodes (28%–60%), peritoneal carcinomatosis (20%–21%), lungs (21%–22%), and bone metastases (13%–17%). The incidence of locoregional recurrence is variable from 33% to 60%, but it is usually combined with distant metastasis (50%–100%) (40, 41).

In the present study, a total of 128 patients (44.8%) developed disease relapse, with 26 patients having more than one site of metastases. Thirty-three patients (25.8%) suffered from locoregional recurrence, while 30 patients (23.4%) had liver metastasis. Other sites of metastases included peritoneal carcinomatosis (13 cases), lungs (10 cases, 7.8%), and para-aortic or SMA lymph node (10 cases, 7.8%). The recurrence patterns were similar in the early- and late-recurrence groups.

Reports on the use of adjuvant therapy following radical resection of ampullary carcinoma are rare (28). Bakkevold et al. found that combined chemotherapy regimens can delay the incidence of recurrence in the first years, but an increase in cure rate was not observed (29). Furthermore, a combination of inoperative radiation and resection did not benefit patients with ampullary cancer. However, Lee and Willett et al. found that the combination of adjuvant chemotherapy and radiation therapy resulted in good local control in high-risk patients, but no improvement in survival (30–32). Mehta et al. proved that adjuvant chemoradiotherapy for ampullary cancer was well tolerated (33), but Sikora et al. found no improvement in long-term survival and no decrease

### TABLE 4 | Variables on disease-specific survival in 286 patients with ampullary of Vater cancer who underwent radical surgery.

| Variables               | No. patients | Mean survival time (months) | 3-year survival rate (%) | 5-year survival rate (%) | P value |
|-------------------------|--------------|----------------------------|--------------------------|--------------------------|---------|
| Tumor stage, n (%)      |              |                            |                          |                          | <0.001  |
| T1                      | 56           | 88.7                       | 92.3                     | 75.8                     |         |
| T2                      | 83           | 92.5                       | 76.6                     | 65.7                     |         |
| T3                      | 93           | 68.2                       | 52.5                     | 35.9                     |         |
| T4                      | 54           | 58.1                       | 51.0                     | 35.7                     |         |
| Resection margin, n (%) |              |                            |                          |                          | <0.01   |
| R0                      | 281          | 92.9                       | 70.0                     | 55.9                     |         |
| R1                      | 5            | 33.0                       | 30.0                     | 0.0                      |         |
| Lymph node status, n (%)|              |                            |                          |                          | <0.001  |
| Negative                | 204          | 98.6                       | 78.7                     | 62.4                     |         |
| Positive                | 82           | 68.1                       | 50.0                     | 38.0                     |         |
| Lymphovascular invasion |              |                            |                          |                          | <0.001  |
| Negative                | 198          | 93.4                       | 76.6                     | 61.4                     |         |
| Positive                | 88           | 73.5                       | 51.9                     | 41.3                     |         |
| Perineural invasion     |              |                            |                          |                          | <0.001  |
| Negative                | 230          | 100.6                      | 75.4                     | 61.0                     |         |
| Positive                | 56           | 43.8                       | 47.5                     | 30.2                     |         |
| Differentiation, n (%)  |              |                            |                          |                          | <0.001  |
| Well                    | 106          | 119.2                      | 87.5                     | 77.5                     |         |
| Moderate                | 156          | 71.5                       | 62.7                     | 44.2                     |         |
| Poor                    | 24           | 49.1                       | 43.3                     | 40.5                     |         |
| AJCC TNM Stage, n (%)   |              |                            |                          |                          | <0.001  |
| Stage I                 | 117          | 94.8                       | 86.8                     | 72.1                     |         |
| Stage II                | 113          | 73.9                       | 60.5                     | 39.9                     |         |
| Stage III               | 56           | 64.3                       | 56.8                     | 31.7                     |         |
| Chemotherapy            |              |                            |                          |                          | <0.001  |
| Yes                     | 89           | 42.6                       | 44.5                     | 26.3                     |         |
| No                      | 197          | 106.6                      | 75.6                     | 61.4                     |         |

### TABLE 5 | Multivariate analysis in the recurrence group.

| Group         | Variables               | Relative risk | 95% Confidence interval | P value |
|---------------|-------------------------|---------------|-------------------------|---------|
| Early recurrence | Histologic differentiation | 2.4           | 1.9-3.9                 | <0.01   |
|               | Lymphovascular invasion   | 2.2           | 1.5-3.0                 | <0.01   |
|               | Peritoneal seeding        | 12.2          | 5.6-43.8                | <0.01   |
|               | Multiple metastasis       | 6.7           | 2.4-18.3                | <0.01   |
| Late recurrence | Lymphovascular invasion   | 2.5           | 1.2-3.7                 | <0.01   |
|               | Peritoneal seeding        | 6.9           | 3.5-9.6                 | <0.01   |
|               | Multiple metastasis       | 5.4           | 2.1-7.8                 | <0.01   |
in recurrence rates (3,4). Earlier studies indicated no known proper and adequate regimen of chemoradiotherapy for patients with ampullary cancer. Therefore, a prospective randomized study based on histopathologic or clinical predictors is necessary to elucidate the effect of adjuvant therapy on high-risk patients. Based on the results of pancreatic cancer studies, several institutions have extrapolated the incorporation of adjuvant therapy in patients with ampullary cancer. However, the use of adjuvant therapy in this setting is controversial. The results of a 1999 trial of the European Organization for Research and Treatment of Cancer demonstrated no statistically significant benefit in survival with adjuvant chemotherapy following resection for ampullary adenocarcinoma. In the present study, patients with resected ampullary adenocarcinoma do appear to benefit from adjuvant chemotherapy.

This study had some limitations concerning its retrospective nature. Though there were limitations in this study, the differences between groups were remarkable. In conclusion, lymph node involvement, lymphovascular invasion, peritoneal metastases, histologic differentiation, and AJCC TNM stage were significant predictors of recurrence. Lymphovascular invasion and histologic differentiation were significant histologic predictors of survival in patients with ampullary cancer. The most common patterns of postoperative recurrence are locoregional and recurrent liver metastasis. The recurrence patterns with the worst prognosis were peritoneal and multiple metastases. Postoperative regional therapy is recommended for patients with pancreatic invasion to decrease locoregional recurrence.

REFERENCES
1. Askew J, Connor S. Review of the investigation and surgical management of resectable ampullary adenocarcinoma. HPB (Oxford) (2013); 15:829–38. doi: 10.1111/hpb.12038
2. Adsay V, Ohike N, Tajiri T, Kim GE, Krasinskas A, Balci S, et al. Ampullary region carcinomas: definition and site specific classification with delineation of four clinicopathologically and prognostically distinct subsets in an analysis of 249 cases. Am J Surg Pathol. (2012); 36:1592–608. doi: 10.1097/PAS.0b013e31826399d8
3. Hornick JR, Johnston FM, Simon PO, Younkin M, Chamberlin M, Mitchem JB, et al. A single-institution review of 157 patients presenting with benign and malignant tumors of the ampulla of Vater: management and outcomes. Surgery. (2011); 150:169–76. doi: 10.1016/j.surg.2011.05.012
4. Chen SC, Shyr YM, Wang SE. Longterm survival after pancreaticoduodenectomy for periampullary adenocarcinomas. HPB (Oxford) (2013); 15:951–7. doi: 10.1111/hpb.12071
5. Ramfidis VS, Syrigos KN, Saif MW. Ampullary and periampullary adenocarcinoma: new challenges in management of recurrence. JOP. (2013); 14:158–60. doi: 10.6092/1590-8577/1471
6. Shinkawa H, Takenuma S, Kiyota S, Uenishi T, Kaneda K, Sakae M, et al. Long-term outcome of surgical treatment for ampullary carcinoma. Hepatogastroenterology. (2012); 59:1010–12. doi: 10.5754/hge10788
7. Kim WS, Choi DW, Choi SH, Heo JS, You DD, Lee HG. Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer. J Surg Oncol. (2012); 105:266–72. doi: 10.1002/jso.22090
8. Showalter TN, Zhan T, Anne PR, Chervoneva I, Mitchell EP, Yeo CJ, et al. The influence of prognostic factors and adjuvant chemoradiation in survival after pancreaticoduodenectomy for ampullary carcinoma. J Gastrointest Surg. (2011); 15:1411–6. doi: 10.1007/s11605-011-1518-6
9. Chun YS, Pawlik TM, Vauthey JN. 8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers. Ann Surg Oncol. (2018); 25:845–7. doi: 10.1245/s10434-017-6025-x
10. Hwang S, Lee SG, Lee YJ, Han DJ, Kim SC, Kwon SH, et al. Radical surgical resection for carcinoid tumors of the ampulla. J Gastrointest Surg. (2008); 12:713–7. doi: 10.1016/j.jgastro.2007-03839-3
11. Witzgann H, Möbius C, Uhlmann D, Geissler F, Tannapfel A, Halm U, et al. Treatment concept of adenomas of Vater’s ampulla. Chirurg. (2000); 71:196–201. doi: 10.1007/s001040050033
12. Michelassi F, Erroi F, Dawson PJ, Pietrabissa A, Noda S, Handcock M, et al. Experience with 647 consecutive tumors of the duodenum, ampulla, head of the pancreas, and distal common bile duct. Ann Surg. (1989); 210:544–54. doi: 10.1097/00000658-198910000-00015
13. Akbulut S, Sahin TT, Yılmaz S. Comment on pediatric living donor liver transplantation decade progress in Shanghai: Characteristics and risks factors of mortality. World J Gastroenterol. (2020); 26:4564–6. doi: 10.3748/wjg/v26.i30.4564
14. Shimizu Y, Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Miyazaki M. The morbidity, mortality, and prognostic factors for ampullary carcinoma and distal cholangiocarcinoma. Hepatogastroenterology. (2008); 55:699–703. PMID: 18613437
15. Woo SM, Ryu JK, Lee SH, Yoo JW, Park JK, Kim YT, et al. Recurrence and prognostic factors of ampullary carcinoma after radical resection: comparison with distal extrahepatic cholangiocarcinoma. Ann Surg Oncol. (2007); 14:395–201. doi: 10.1245/s10434-007-9537-y
16. Dolay K, Malya FU, Akbulut S. Management of pancreatic head adenocarcinoma: From where to where? World J Gastrointest Surg. (2019); 11:143–54. doi: 10.4240/wjgs.v11.i3.143

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by the ethics committee of Shanghai Jiaotong University. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS
Z-QZ and Z-YZ designed the study and supervised the data collection. Z-YZ, D-WL, D-SH and Z-QZ analyzed the data and interpreted the data. Z-QZ and Z-YZ prepared the manuscript for publication and reviewed the draft of the manuscript. All authors have read and approved the manuscript.

FUNDING
Zheng-Yun Zhang is currently receiving a grant (81974379) from the National Natural Science Foundation of China. Zun-Qiang Zhou is currently receiving a grant (19ZR1438700) from the Natural Science Foundation of Shanghai and a grant (ZH2018QNB05) from the Interdisciplinary Program of Shanghai Jiao Tong University.
17. Kim RD, Kundhal PS, McGivney ID, Cattral MS, Taylor B, Langer B, et al. Predictors of failure after pancreaticoduodenectomy for ampullary carcinoma. J Am Coll Surg. (2006); 202:112–9. doi: 10.1016/j.jamcollsurg.2005.08.002

18. Qiao QL, Zhao YG, Ye ML, Yang YM, Zhao JX, Huang YT, et al. Carcinoma of the ampulla of Vater: factors influencing long-term survival of 127 patients with resection. World J Surg. (2007); 31:137–43; discussion 144–136. doi: 10.1007/s00268-006-0213-3

19. Albores-Saavedra J, Schwartz AM, Batich K, Henson DE. Cancers of the ampulla of Vater: demographics, morphology, and survival based on 5625 cases from the SEER program. J Surg Oncol. (2009); 100:598–605. doi: 10.1002/jso.21374

20. Klempnauer J, Ridder GJ, Pichlmayr R. Prognostic factors after resection of tumor spread in adenocarcinoma of the ampulla of Vater. Arch Surg. (1999); 134:526–32. doi: 10.1001/archsurg.134.5.526

21. Delcore R Jr, Connor CS, Thomas JH, Friesen SR, Hermreck AS. Significance of histologic type and perineural invasion as prognostic factors after curative resection of ampulla carcinoma. Hepatogastroenterology. (2010); 57:646–52. PMID: 20698243

22. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. (1999); 230:776–82. doi: 10.1097/00000658-199912000-00006

23. Beger HG, Treitschke F, Gansauge F, Harada N, Hiki N, Mattfeldt T. Tumor involvement in ampullary cancer: implications for surgical strategy and long-term prognosis. J Gastrointest Surg. (2010); 14:379–87. doi: 10.1007/s11605-009-1080-7

24. Sikora SS, Balachandran P, Dinmri K, Rastogi N, Kumar A, Saxena R, et al. Adjuvant chemoradiotherapy in ampullary cancers. Eur J Surg Oncol. (2005); 31:158–63. doi: 10.1016/j.ejso.2004.08.013

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zhang, Liu, Hao and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.